Better Health for All

Inspira Technologies' core products, such as the INSPIRA™ ART100 system and the HYLA™ blood sensor, are designed to deliver significant health benefits. The ART100 system aims to improve patient oxygen saturation, potentially reducing the need for mechanical ventilation and allowing patients to remain awake during treatment.

The HYLA sensor achieved 96% accuracy in a key blood parameter and 92.3% accuracy in detecting oxygen deficiencies in a clinical study, enabling real-time monitoring. A collaboration also showed a 95% reduction in bacterial presence for preventing bloodstream infections. The company's entire product portfolio focuses on life support and monitoring technologies, indicating no revenue from products with negative health outcomes. The INSPIRA™ ART100 system is designed to reduce staff overhead and improve efficiency during critical procedures. While the HYLA sensor's ability to detect oxygen deficiencies and the Ennocure collaboration's focus on preventing bloodstream infections demonstrate an emphasis on preventative health, there is no quantitative data on the percentage of health-related expenditure allocated to prevention.

Fair Money & Economic Opportunity

Inspira Technologies Oxy B.H.N. Ltd. is a medical technology company focused on respiratory support technology.

Its core business does not involve offering lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to the company's operations. No evidence in the provided articles suggests the company offers consumer financial products, manages customer finance data, or engages in activities that would directly impact financial inclusion or economic opportunity for marginalized populations.

Fair Pay & Worker Respect

None of the 33 full-time employees located in Israel are represented by labor unions or covered by collective bargaining agreements.

Employee engagement is low, with an average rating of 2.8 out of 5 stars and only 37% of employees stating they would recommend working there. Voluntary employee turnover is described as 'high turnover because of understaffing and poor management'. The company has a clean record with zero fines or violations in the past two years.

Kind to Animals

Inspira Technologies conducted in-vivo animal testing using 80 kg swine at the Institute of Animal Research in Israel to assess the gas exchange efficiency of their VORTX™ technology

, , , , , , . The company's core business involves developing medical devices, which often necessitates animal testing for safety and efficacy. However, there is no information available regarding the company's animal testing policies, alternative testing usage, or efforts to reduce animal testing. The absence of this information prevents a more precise assessment. Given the animal testing and lack of information on alternatives, a score of -10 is appropriate. This reflects the use of animals in testing without evidence of efforts to mitigate harm. More information on animal welfare policies and alternative testing methods would be needed for a more accurate assessment.